Tak Peter Paul's most recent trade in Candel Therapeutics Inc was a trade of 25,772 Common Stock done at an average price of $8.8 . Disclosure was reported to the exchange on March 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Candel Therapeutics Inc | Paul Peter Tak | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 8.77 per share. | 18 Mar 2025 | 25,772 | 226,140 | - | 8.8 | 226,023 | Common Stock |
| Candel Therapeutics Inc | Paul Peter Tak | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 9.00 per share. | 18 Mar 2025 | 400 | 225,740 | - | 9.0 | 3,601 | Common Stock |
| Candel Therapeutics Inc | Paul Peter Tak | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 525,000 | 525,000 | - | - | Stock Option (Right to Buy) | |
| Candel Therapeutics Inc | Paul Peter Tak | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.22 per share. | 15 Jan 2025 | 21,704 | 251,912 | - | 7.2 | 156,811 | Common Stock |
| Candel Therapeutics Inc | Tak Peter Paul | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.56 per share. | 29 Nov 2024 | 48,847 | 294,788 | - | 4.6 | 222,527 | Common Stock |
| Candel Therapeutics Inc | Paul Peter Tak | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2024 | 12,900 | 1,763,968 | - | - | Stock Option (Right to Buy) | |
| Candel Therapeutics Inc | Paul Peter Tak | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.55 per share. | 21 Nov 2024 | 12,900 | 343,635 | - | 1.6 | 19,995 | Common Stock |
| Candel Therapeutics Inc | Tak Peter Paul | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.47 per share. | 17 Jul 2024 | 22,528 | 330,735 | - | 6.5 | 145,815 | Common Stock |
| Candel Therapeutics Inc | Paul Peter Tak | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 5.97 per share. | 11 Jul 2024 | 20,293 | 353,263 | - | 6.0 | 121,218 | Common Stock |
| Candel Therapeutics Inc | Paul Peter Tak | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 180,000 | 180,000 | - | - | Stock Option (Right to Buy) | |
| Candel Therapeutics Inc | Paul Peter Tak | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.92 per share. | 08 Dec 2022 | 12,935 | 40,985 | - | 1.9 | 24,835 | Common Stock |
| Candel Therapeutics Inc | Paul Peter Tak | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.70 per share. | 08 Dec 2022 | 3,050 | 28,050 | - | 1.7 | 5,185 | Common Stock |
| Candel Therapeutics Inc | Paul Peter Tak | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Nov 2022 | 195,906 | 220,906 | - | 0 | Common Stock | |
| Candel Therapeutics Inc | Paul Peter Tak | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 330,000 | 330,000 | - | - | Stock Option (Right to Buy) | |
| Candel Therapeutics Inc | Paul Peter Tak | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 8.00 per share. | 29 Jul 2021 | 25,000 | 25,000 | - | 8 | 200,000 | Common Stock |